A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

Abstract: The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients ≥60 years with FMS-like tyrosine kinase 3 (FLT3)–mutated acute myeloid leukemia (AML). In this study, sorafenib was added to dau...

Full description

Bibliographic Details

Published in:	Blood Advances
Main Authors:	Geoffrey L. Uy, Sumithra J. Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J. Levis, Heidi D. Klepin, Maria R. Baer, Bayard L. Powell, Peter Westervelt, Daniel J. DeAngelo, Wendy Stock, Ben Sanford, William G. Blum, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Format:	Article
Language:	English
Published:	Elsevier 2017-01-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2473952920304158